Boswellia, also known as Indian frankincense, is an herbal extract derived from the resin of Boswellia serrata trees. Its use in Inflammatory Bowel Disorders (IBD), such as ulcerative colitis and Crohn’s disease, is primarily supported by emerging scientific evidence. Several clinical trials, mostly small and preliminary, have investigated Boswellia’s efficacy in IBD. The resin contains boswellic acids, which exhibit anti-inflammatory effects by inhibiting 5-lipoxygenase and thus reducing leukotriene synthesis—a pathway implicated in the pathophysiology of IBD.

Notably, a randomized, double-blind study published in the journal European Journal of Medical Research (1997) compared Boswellia extract to sulfasalazine in patients with chronic colitis. The Boswellia group showed comparable rates of clinical improvement and remission, suggesting a potential benefit. Further trials and meta-analyses have provided moderate evidence for Boswellia’s safety and efficacy, though the overall quality and size of studies are limited. Boswellia’s anti-inflammatory mechanisms and its potential to reduce disease activity in IBD have garnered interest, but larger, high-quality randomized controlled trials are needed to confirm its role.

In summary, while Boswellia has a traditional use in Ayurvedic medicine for inflammatory conditions, its application in IBD is increasingly supported by scientific investigation. Current evidence suggests moderate efficacy and safety, warranting cautious optimism but not replacing standard therapies.